Who Paid My Doc
A Phase 2B, Randomized, Observer-Blinded Trial to Describe the Safety,
Research payments
$1,360,037
Through program year 2025, $1,360,037 in research payments was reported against A Phase 2B, Randomized, Observer-Blinded Trial to Describe the Safety,, across 600 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $127,826 | 139 |
| 2024 | Research | $320,262 | 157 |
| 2023 | Research | $240,003 | 151 |
| 2022 | Research | $671,947 | 153 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- William Johnston Birmingham, AL Named on 29 payments
- Daniel Leonard Grand Island, NE Named on 26 payments
- Frank Calcagno Portland, OR Named on 25 payments
- Michael Simon Lexington, KY Named on 24 payments
- Merlin Fausett Missoula, MT Named on 20 payments
- Richard Rupp Galveston, TX Named on 17 payments
- Frank Eder Binghamton, NY Named on 17 payments
- Joseph Ley Kingsport, TN Named on 16 payments
- Eric Lorraine Johnson City, NY Named on 14 payments
- Frederick Raiser Omaha, NE Named on 13 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.